| 来源类型 | Working Paper
|
| 规范类型 | 报告
|
| DOI | 10.3386/w26892
|
| 来源ID | Working Paper 26892
|
| The Rise of For-Profit Experimental Medicine |
| Pierre Azoulay; Ariel Fishman
|
| 发表日期 | 2020-03-30
|
| 出版年 | 2020
|
| 语种 | 英语
|
| 摘要 | Beginning around 1990, academic medical centers have ceased to be the primary locus of industry-sponsored clinical trial activity. Instead, clinical trials have increasingly been conducted in private practices and for-profit, dedicated study sites. We examine the underlying causes of this startling evolution. On the demand side, the greater availability of non-academic investigators has enabled pharmaceutical firms to better match physicians' skills with specific projects. On the supply side, we argue that the growth of managed care health insurance has contributed to a rise in the number of non-academic physicians performing clinical research. We find evidence consistent with these claims using a unique data set containing information about 85,919 site contracts for 7,735 clinical trials between 1991 and 2003. Furthermore, we examine the gap in prevailing prices for comparable procedures conducted for clinical trials versus conventional medical care, and conclude that the effect of managed care on entry is consistent with non-academic physicians “inducing demand” so as to resist downward pressures on their income. |
| 主题 | Health, Education, and Welfare
; Health
; Education
; Development and Growth
; Innovation and R&
; D
|
| URL | https://www.nber.org/papers/w26892
|
| 来源智库 | National Bureau of Economic Research (United States)
|
| 引用统计 |
|
| 资源类型 | 智库出版物
|
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/584565
|
推荐引用方式
GB/T 7714 |
Pierre Azoulay,Ariel Fishman. The Rise of For-Profit Experimental Medicine. 2020.
|
|
文件名：
|
w26892.pdf
|
|
格式：
|
Adobe PDF
|
此文件暂不支持浏览
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
